Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun 9;15(12):3125.
doi: 10.3390/cancers15123125.

Role of Syndecans in Ovarian Cancer: New Diagnostic and Prognostic Biomarkers and Potential Therapeutic Targets

Julia Oto  1   2 , Quang-Khoi Le  1 , Sebastian D Schäfer  1 , Ludwig Kiesel  1 , Josep Marí-Alexandre  3   4 , Juan Gilabert-Estellés  3   5   6 , Pilar Medina  2 , Martin Götte  1
Affiliations
Review

Role of Syndecans in Ovarian Cancer: New Diagnostic and Prognostic Biomarkers and Potential Therapeutic Targets

Julia Oto et al. Cancers (Basel). .

Abstract

Ovarian cancer (OC) is the eighth cancer both in prevalence and mortality in women and represents the deadliest female reproductive cancer. Due to generally vague symptoms, OC is frequently diagnosed only at a late and advanced stage, resulting in high mortality. The tumor extracellular matrix and cellular matrix receptors play a key role in the pathogenesis of tumor progression. Syndecans are a family of four transmembrane heparan sulfate proteoglycans (PG), including syndecan-1, -2, -3, and -4, which are dysregulated in a myriad of cancers, including OC. Many clinicopathological studies suggest that these proteins are promising diagnostic and prognostic biomarkers for OC. Furthermore, functions of the syndecan family in the regulation of cellular processes make it an interesting pharmacological target for anticancer therapies.

Keywords: diagnosis biomarker; ovarian cancer; prognosis biomarker; proteoglycan; syndecan family; syndecan-1; syndecan-2; syndecan-3; syndecan-4; therapeutic target.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overview of the value of the syndecan family as diagnostic biomarkers and therapeutic targets in ovarian cancer. SDC1: Syndecan-1; SDC2: Syndecan-2; SDC3: Syndecan-3; SDC4: Syndecan-4; HS: Heparan sulfate; CS: Chondroitin sulfate; C1: Constant domain 1; C2: Constant domain 2; V: Variable domain.
Figure 2
Figure 2
Prognostic value of syndecan family members expression for overall survival of patients with ovarian cancer based on the dataset of the Kaplan–Meier plotter [29] (data retrieved on 15 March 2023). The default settings in the KM Plotter tool were used to calculate the overall survival. (A) SDC1 (syndecan-1), (B) SDC2 (HSPG1, syndecan-2), (C) SDC3 (syndecan-3), (D) SDC4 (syndecan-4).
Figure 3
Figure 3
Prognostic value of syndecan family member expression for progression-free survival of patients with ovarian cancer based on the Kaplan–Meier plotter [29] (data retrieved on 15 March 2023). The default settings in the KM Plotter tool were used to calculate the progression-free survival. (A) SDC1 (syndecan-1), (B) SDC2 (HSPG1, syndecan-2), (C) SDC3 (syndecan-3), (D) SDC4 (syndecan-4).
Figure 4
Figure 4
Prognostic value of syndecan family member expression for post-progression survival of patients with ovarian cancer based on the Kaplan–Meier plotter [29] (data retrieved on 15 March 2023). The default settings in the KM Plotter tool were used to calculate the post-progression survival. (A) SDC1 (syndecan-1), (B) SDC2 (HSPG1, syndecan-2), (C) SDC3 (syndecan-3), (D) SDC4 (syndecan-4).
See this image and copyright information in PMC

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Stewart C., Ralyea C., Lockwood S. Ovarian Cancer: An Integrated Review. Semin. Oncol. Nurs. 2019;35:151–156. doi: 10.1016/j.soncn.2019.02.001. - DOI - PubMed
    1. Webb P.M., Jordan S.J. Epidemiology of epithelial ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 2017;41:3–14. doi: 10.1016/j.bpobgyn.2016.08.006. - DOI - PubMed
    1. Atallah G.A., Abd Aziz N.H., Teik C.K., Shafiee M.N., Kampan N.C. New Predictive Biomarkers for Ovarian Cancer. Diagnostics. 2021;11:465. doi: 10.3390/diagnostics11030465. - DOI - PMC - PubMed
    1. Karamanos N.K., Piperigkou Z., Passi A., Gotte M., Rousselle P., Vlodavsky I. Extracellular matrix-based cancer targeting. Trends Mol. Med. 2021;27:1000–1013. doi: 10.1016/j.molmed.2021.07.009. - DOI - PubMed

LinkOut - more resources